J Clin Pharmacol. 2016 Apr;56(4):439-49. doi: 10.1002/jcph.614. Epub 2015 Nov 17.

Population plasma and urine pharmacokinetics of ivabradine and its active metabolite  S18982 in healthy Korean volunteers.

Choi HY, Bae KS, Cho SH, Ghim JL, Choe S, Jung JA, Lim HS.

Abstract

Ivabradine, a selective inhibitor of the pacemaker current (If ), is used for heart failure and coronary heart disease and is mainly metabolized to S18982. The purpose of this study was to explore the pharmacokinetics (PK) of ivabradine and S18982 in healthy Korean volunteers. Subjects in a phase I study were randomized to receive 2.5, 5, or 10 mg of ivabradine administered every 12 hours for 4.5 days, and serial plasma and urine concentrations of ivabradine and S18982 were measured. The plasma PK of ivabradine was best described by a 2-compartment model with mixed 0- and first-order absorption, linked to a 2-compartment model for S18982. The introduction of interoccasional variabilities and period as covariate into absorption-related parameters improved the model fit. Urine data have been applied to estimate renal and nonrenal clearance, enabling a more detailed description of the elimination process. We developed a population PK model describing the plasma and urine PK of ivabradine and S18982 in healthy Korean adult males. This model might be useful for predicting the plasma and urine PK of ivabradine, potentially helping to identify the optimal dosing regimens in various clinical situations.

KEYWORDS:

NONMEM; S18982; ivabradine; plasma pharmacokinetics; urine pharmacokinetics

PMID:

26265098

DOI:

10.1002/jcph.614